Komoriya K, Nagata I, Tsuchimoto M, Kunisawa K, Koyama T, Hosoda K, Takeshita T, Naruchi T, Yamamoto I, Abe C
Immunopharmacology. 1987 Apr;13(2):89-98. doi: 10.1016/0162-3109(87)90045-2.
TI-31 (TEI-3096; 6-p-chlorobenzyl-5H-2,3,6,7-tetrahydro-5,7-dioxothiazolo[3,2-a]pyr imidine) is a novel immunomodulator. Various nephritic changes observed in female NZB/NZW F1 (B/W) mice with aging were suppressed by TI-31 when administered orally 5 times per week for 16 weeks at doses of 2, 10, or 50 mg/kg. It suppressed proteinuria, oliguria, the decrease of erythrocyte count, and increase of serum urea nitrogen, immune complex and anti-double-stranded DNA antibody levels. The anti-nephritic effect of TI-31 was confirmed by histopathological evaluation. TI-31 (10 mg/kg) could improve both the elevated polyclonal B cell activation and the depressed antibody response to sheep red blood cells in B/W mice, in comparison with age- and sex-matched BALB/c mice, without any effect on the antibody response in these normal mice. These findings indicate that TI-31 may inhibit B/W nephritis by regulating the antibody production through a mechanism different from that of anti-inflammatory drugs or immunosuppressants.
TI-31（TEI-3096；6-对氯苄基-5H-2,3,6,7-四氢-5,7-二氧代噻唑并[3,2-a]嘧啶）是一种新型免疫调节剂。当以2、10或50mg/kg的剂量每周口服给药5次，持续16周时，TI-31可抑制雌性NZB/NZW F1（B/W）小鼠随着年龄增长而出现的各种肾炎变化。它抑制了蛋白尿、少尿、红细胞计数的减少以及血清尿素氮、免疫复合物和抗双链DNA抗体水平的升高。TI-31的抗肾炎作用通过组织病理学评估得到证实。与年龄和性别匹配的BALB/c小鼠相比，TI-31（10mg/kg）可改善B/W小鼠中升高的多克隆B细胞活化和对绵羊红细胞的抗体反应降低的情况，而对这些正常小鼠的抗体反应没有任何影响。这些发现表明，TI-31可能通过一种不同于抗炎药或免疫抑制剂的机制调节抗体产生，从而抑制B/W肾炎。
